https://pubmed.ncbi.nlm.nih.gov/39727048/ MASLD

Review

J Pediatr Gastroenterol Nutr. 2024 Dec 27.
doi: 10.1002/jpn3.12399.Online ahead of print.

FISPGHAN statement on the global public health impact of metabolic dysfunction-associated steatotic liver disease

Tania Mitsinikos 1 2, Marion M Aw 3 4, Robert Bandsma 5, Marcela Godoy 6 7, Samar H Ibrahim 8, Jake P Mann 9, Iqbal Memon 10, Neelam Mohan 11, Nezha Mouane 12, Gilda Porta 13, Elvira Verduci 14 15, Stavra Xanthakos 16
Affiliations expand
PMID: 39727048

DOI: 10.1002/jpn3.12399

Abstract

As rates of obesity rise worldwide, incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease, is increasing, worsening the burden of healthcare systems. The council of the Federation of International Societies for Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN) identified the topic of MASLD epidemiology, treatment, and prevention as a global priority issue to be addressed by an expert team, with the goal to describe feasible and evidence-based actions that may contribute to reducing MASLD risk. The FISPGHAN member societies nominated experts in the field. The FISPGHAN council selected and appointed members of the expert team and a chair. The subtopics included in this manuscript were chosen through a consensus of the experts involved. We review the epidemiology, natural history, and screening and management. We further expand to relevant public health measures aimed at MASLD prevention, including identifying interventions that could reduce risk factors (environmental and iatrogenic), optimize maternal and newborn health, and support healthier lifestyles for older children and adolescents on a local, national, and international scale. While recognizing that various aspects of population health and public policy can shape MASLD risk, we also review what we can do on an individual level to support our patients to reduce the significant burden of this ever rising disease in pediatrics.